NovoCure (NVCR) Profit After Tax (QoQ) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -190.37% |
| Dec 31, 2025 | 34.27% |
| Sep 30, 2025 | 7.15% |
| Jun 30, 2025 | -16.96% |
| Mar 31, 2025 | 47.94% |
| Dec 31, 2024 | -115.64% |
| Sep 30, 2024 | 8.40% |
| Jun 30, 2024 | 13.89% |
| Mar 31, 2024 | 17.67% |
| Dec 31, 2023 | 4.86% |
| Sep 30, 2023 | 13.82% |
| Jun 30, 2023 | -8.21% |
| Mar 31, 2023 | -42.24% |
| Dec 31, 2022 | -40.36% |
| Sep 30, 2022 | -10.70% |
| Jun 30, 2022 | -416.63% |
| Mar 31, 2022 | 82.44% |
| Dec 31, 2021 | -101.60% |
| Sep 30, 2021 | 10.36% |
| Jun 30, 2021 | -254.68% |
| Mar 31, 2021 | -183.95% |
| Dec 31, 2020 | -47.04% |
| Sep 30, 2020 | 460.97% |
| Jun 30, 2020 | -58.12% |
| Mar 31, 2020 | -7.23% |
| Dec 31, 2019 | 120.73% |
| Sep 30, 2019 | 251.97% |
| Jun 30, 2019 | 89.55% |
| Mar 31, 2019 | 22.27% |
| Dec 31, 2018 | -33.67% |
| Sep 30, 2018 | 24.60% |
| Jun 30, 2018 | 25.16% |
| Mar 31, 2018 | -89.35% |
| Dec 31, 2017 | 4.81% |
| Sep 30, 2017 | 45.70% |
| Jun 30, 2017 | -17.34% |
| Mar 31, 2017 | 18.60% |
| Dec 31, 2016 | 34.08% |
| Sep 30, 2016 | 17.20% |
| Jun 30, 2016 | -14.60% |
| Mar 31, 2016 | -7.62% |
| Dec 31, 2015 | -26.53% |
| Sep 30, 2015 | 11.36% |
| Jun 30, 2015 | -26.14% |
| Mar 31, 2015 | -1.56% |
| Dec 31, 2014 | -25.09% |